Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series
- PMID: 31017658
- DOI: 10.1111/bjd.18031
Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series
References
-
- Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.
-
- Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389:2287-303.
-
- Summary of Product Characteristics (SmPC). Dupixent. Available at: https://www.medicines.org.uk/emc/product/8553 (last accessed 19 February 2019).
-
- Ou Z, Chen C, Chen A et al. Adverse events of dupilumab in adults with moderate-to-severe atopic. Int Immunopharmacol 2018; 54:303-10.
-
- Joosten LA, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-60.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical